anti-human VEGFR-2/KDR monoclonal antibody Anti-Human 100 µg
Description / anti-human VEGFR-2/KDR monoclonal antibody
VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.
More Information
| Size | 100 µg |
|---|---|
| Source | Mouse |
| Isotype | IgG1 |
| Biological Activity | ELISA: Use at 1-10 µg/ml; WB: Use at 2-5 µg/ml; Immunohistochemistry: Use at 6-30 µg/ml; FACS analysis: Use at 2-10 µg/ml. |
| Clone Nr. | (#EIC) |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
| Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% |
| Preparation | The monoclonal antibody was produced with the help of BALB/c mice using recombinant human soluble extracellular KDR (110 kDa) as the immunizing antigen. |
| Antigen | recombinant human soluble extracellular KDR (D7) |
| Application | ELISA, IHC, FC, WB |
| Synonyms | vascular endothelial growth factor receptor-2 ; KDR; FLK1; CD309; VEGF receptor 2; VEGFR2; kinase insert domain protein receptor |
| Uniprot ID | P35968 |
| Protein RefSeq | NP_002244.1 |
| mRNA RefSeq | NM_002253.2 |